5-Amino-1MQ vs Tirzepatide
preclinical vs FDA Approved
compatible NNMT inhibition may complement GLP-1 effects for metabolic optimization.
Molecular Data
5-Amino-1MQ Tirzepatide
Weight — 4,813.55 Da
Half-life 4-7 hours (3.8h IV, 6.9h oral) ~5 days (120 hours)
Chain — 39 amino acids
Type Small molecule NNMT enzyme inhibitor Dual GLP-1/GIP agonist
Key Benefits
5-Amino-1MQ
01 Enhanced NAD+ levels
02 Improved mitochondrial function
03 Better energy metabolism
04 Enhanced cellular repair
05 Improved insulin sensitivity
06 Longevity support
07 Convenient daily oral dosing
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
5-Amino-1MQ
50-100mg oral or 150-500mcg SubQ / Once daily, preferably morning
Conservative starting (mcg protocol) 150-250mcg 1x daily
Conservative standard (mcg protocol) 250-500mcg 1x daily
Study-based (mg protocol) ~350mg (5mg/kg) 1x daily
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
5-Amino-1MQ
Generally minimal side effects
Occasional mild GI adjustment
Potential sleep interference if dosed late in day
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Pregnancy or breastfeeding
Pre-existing metabolic conditions (consult healthcare provider)
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
5-Amino-1MQ Tirzepatide
Status preclinical FDA Approved
References 3 studies 4 studies
Latest March 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.